Linked Life Data

20674607

Source:http://linkedlifedata.com/resource/pubmed/id/20674607

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-9-6
pubmed:abstractText
Antibody based, high throughput proteomics technology represents an exciting new approach in understanding the pathobiologies of complex disorders such as cancer, stroke and traumatic brain injury. Reverse phase protein microarray (RPPA) can complement the classical methods based on mass spectrometry as a high throughput validation and quantification method. RPPA technology can address problematic issues, such as sample complexity, sensitivity, quantification, reproducibility and throughput, which are currently associated with mass spectrometry-based approaches. However, there are technical challenges, predominantly associated with the selection and use of antibodies, preparation and representation of samples and with analyzing and quantifying primary RPPA data. Here we present ways to identify and overcome some of the current issues associated with RPPA. We believe that using stringent quality controls, improved bioinformatics analysis and interpretation of primary RPPA data, this method will significantly contribute in generating new level of understanding about complex disorders at the level of systems biology.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1872-678X
pubmed:author
pubmed:copyrightInfo
Published by Elsevier B.V.
pubmed:issnType
Electronic
pubmed:day
30
pubmed:volume
192
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
96-101
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Reverse phase protein microarray technology in traumatic brain injury.
pubmed:affiliation
Department of Anatomy, Physiology and Genetics, School of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD 20814, USA. agyorgy@usuhs.mil
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.